Moderna (MRNA, $58.57) might be delaying start of Phase 3 trial of covid-19 vaccine
Biotech company Moderna has reportedly delayed the start of a Phase III trial of its coronavirus vaccine.
The healthcare website Stat News reported that Moderna was making changes to the trial plan, and therefore the start date of the Phase III study has been pushed back, according to investigators who did not want to be named.
“My understanding was that they wanted to get the first vaccines given in July, and they say they’re still committed to do that,” one investigator said, according to Stat News. “As best I can tell, they’re close to being on target for that.”
Moderna wrote on Twitter that "the trial is still expected to begin in July and we expect to be the first to start a Phase 3 trial."
According to Tickeron, MRNA's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line
This is a Bearish indicator signaling MRNA's price could decline. Traders may explore shorting the ticker or looking at put options. In 10 of 12 cases where MRNA's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 83%.
Current price $58.57 crossed the support line at $59.87 and is trading between $59.87 support and $57.71 support lines. Throughout the month of 06/02/20 - 07/02/20, the price experienced a -2% Downtrend. During the week of 06/25/20 - 07/02/20, the stock fell -6%.
Technical Analysis (Indicators):
Bearish Trend Analysis
The Stochastic Indicator may be shifting from an Uptrend to a Downtrend. In 16 of 21 cases where MRNA's Stochastic indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 76%.
The Momentum Indicator moved below the 0 level on June 26, 2020. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 13 of 21 cases where MRNA's Momentum Indicator fell below the 0 level, its price fell further within the subsequent month. The odds of a continued Downtrend are 62%
The price moved below its 50-day Moving Average, which indicates a reversal from an Uptrend to a Downtrend. In 5 of 9 cases where MRNA's price crossed below its 50-day Moving Average, its price fell further within the subsequent month. The odds of a continued Downtrend are 56%.
Following a 3-day Decline, the ticker is projected to fall further. Considering data from situations where MRNA declined for three days, in 77 of 97 cases, the price rose further within the following month. The odds of a continued Downtrend are 79%.
Bullish Trend Analysis
The lower Bollinger Band was broken -- a price increase is expected as the ticker heads toward the middle band, which indicates a buy or call consideration for traders. In 8 of 8 cases where MRNA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued Uptrend are 90%.
The Aroon Indicator entered an Uptrend today. In 64 of 81 similar cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 64%. During the last month, the daily ratio of advancing to declining volumes was 1.14 to 1.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.21) is normal, around the industry mean (2.02). P/E Ratio (0.00) is within average values for comparable stocks, (64.05). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (4.87). Dividend Yield (0.00) settles around the average of (0.08) among similar stocks. P/S Ratio (201.16) is also within normal values, averaging (1250.07).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MRNA's RSI Oscillator ascends from oversold territory
The RSI Oscillator for MRNA moved out of oversold territory on July 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In of the 36 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on MRNA as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on August 10, 2026. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
MRNA moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for MRNA crossed bearishly below the 50-day moving average on July 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRNA broke above its upper Bollinger Band on August 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MRNA entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.759) is normal, around the industry mean (20.121). P/E Ratio (0.000) is within average values for comparable stocks, (25.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.855). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (11.338) is also within normal values, averaging (466.660).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement